Harvard Apparatus Regenerative Technology Inc
hregen.comHarvard Apparatus Regenerative Technology (NASDAQ: HRGN) is a regenerative medicine development-stage company focused on bioengineered organ implants, with a secondary business selling dietary supplements through its Hong Kong subsidiary, Consumer Health Products. Revenue is generated from product sales of dietary supplements, as the company's core regenerative medicine product candidates, including an esophageal implant granted FDA Orphan Drug Designation in November 2016, have not yet received regulatory approval anywhere in the world. HRGN contracted IQVIA as its CRO to manage its first clinical trial, which activated its first site and began screening patients in Q3 2023, but has experienced delays in patient recruitment due to comorbid conditions among participants, stringent FDA eligibility criteria, and logistical challenges across trial sites. The company operates at a net loss, carries going concern risk, and disclosed in its 10-K filed March 19, 2026 that it may be forced to curtail or cease operations if it does not raise additional capital before or during Q2 2026.
Products & Services
Bioengineered esophageal implant in clinical-stage development (FDA Orphan Drug Designation granted November 2016). Dietary supplements sold through Consumer Health Products subsidiary in Hong Kong.
Revenue Model
Transactional product revenue from dietary supplement sales through Consumer Health Products, a Hong Kong subsidiary. No revenue from regenerative medicine product candidates, which remain in clinical development and lack regulatory approval as of the 10-K filed March 19, 2026.
Customers & Markets
Consumer health products customers for dietary supplements. Target end market for regenerative medicine is patients requiring esophageal reconstruction following cancer, injury, or congenital abnormalities, a rare disease population under the Orphan Drug Act threshold of fewer than 200,000 U.S. persons.
Geographic Exposure
United States (clinical trials, regulatory engagement with FDA). Hong Kong (Consumer Health Products subsidiary). Regulatory filings also reference the European Union and China as intended future markets.
Financial Snapshot
Loading...
